File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Interaction of deleted in liver cancer 1 (DLC1) with tensin2 and its implications in tumor suppression

TitleInteraction of deleted in liver cancer 1 (DLC1) with tensin2 and its implications in tumor suppression
Authors
Issue Date2006
PublisherAmerican Association for Cancer Research
Citation
The 97th AACR Annual Meeting, Washington, D.C., 1-5 April 2006. In Cancer Research, 2006, v. 66 n. 8S, p. 970 Abstract no. 4124 How to Cite?
AbstractLiver cancer (hepatocellular carcinoma, HCC) is a major malignancy worldwide and the second commonest fatal cancer in Asia and Hong Kong. Deleted in liver cancer 1 (DLC1), encoding a Rho GTPase activating protein (RhoGAP), is a recently identified tumor suppressor gene. DLC1 is widely expressed in normal human tissues, but we have shown it is frequently underexpressed in HCC. Rho small GTPases are important regulators in actin cytoskeleton reorganization, cell proliferation, metastasis and tumorigenesis. RhoGAP proteins serve their tumor suppressor function by down-regulating Rho GTPase activity. We have previously characterized DLC1 to be a growth suppressor in HCC cell lines and documented its in vitro RhoGAP activity. Our recent findings have revealed that inhibition of Rho-mediated actin stress fiber formation by DLC1 is associated with its growth suppressive effect. In the present study we have identified tensin2 as the novel binding partner of DLC1 in a yeast two-hybrid library screening. Tensin2 belongs to a new family of focal adhesion proteins that play key roles in cytoskeleton organization and signal transduction. Specific in vitro and in vivo interaction between DLC1 and tensin2 was confirmed by GST pull-down assay and co-immunoprecipitation, respectively. We mapped the minimal interacting domains between two proteins to the phosphotyrosine binding domain of tensin2 and residues 375-509 of DLC1. Dysregulation of tensin proteins has previously been implicated in human cancers. Tensin2 is highly expressed in human liver. Introduction of tensin2 into HCC cell lines with low expression of tensin2 caused significant growth inhibition in colony formation assay and induction of apoptosis. Interaction between DLC1 and tensin2 is of particular interest because both interacting partners exert growth suppressive effect on HCC cell lines. Using reporter assay to investigate the effect of DLC1 and tensin2 on the serum response element (SRE), which is one of the Ras effectors, we found that expression of either DLC1 or tensin2 alone could not inhibit or only slightly inhibited the activation of SRE. The effect of inhibition was enhanced when DLC1 and tensin2 were co-expressed. Our results showed that DLC1 and tensin2 cooperatively inhibited Ras signaling based on their specific interaction. Our findings presented here will derive new insights into the biological functions of tensin2. More importantly, our work suggests a new model for the action of DLC1 in hepatocytes, whereby DLC1-tensin2 complex interacts to effect cytoskeletal reorganization and signaling pathway. We believe that a better understanding of the functional roles of DLC1 and tensin2 will have profound implications for diagnosis and therapeutic intervention of HCC. (This study was funded in part by Association for International Cancer Research and Kadoorie Charitable Foundation - Michael Kadoorie Cancer Genetic Research Program)
Persistent Identifierhttp://hdl.handle.net/10722/96367
ISSN
2015 Impact Factor: 8.556
2015 SCImago Journal Rankings: 5.372

 

DC FieldValueLanguage
dc.contributor.authorKo, FCFen_HK
dc.contributor.authorYam, JWPen_HK
dc.contributor.authorChan, PCYen_HK
dc.contributor.authorJin, Den_HK
dc.contributor.authorNg, IOLen_HK
dc.date.accessioned2010-09-25T16:31:37Z-
dc.date.available2010-09-25T16:31:37Z-
dc.date.issued2006en_HK
dc.identifier.citationThe 97th AACR Annual Meeting, Washington, D.C., 1-5 April 2006. In Cancer Research, 2006, v. 66 n. 8S, p. 970 Abstract no. 4124-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/96367-
dc.description.abstractLiver cancer (hepatocellular carcinoma, HCC) is a major malignancy worldwide and the second commonest fatal cancer in Asia and Hong Kong. Deleted in liver cancer 1 (DLC1), encoding a Rho GTPase activating protein (RhoGAP), is a recently identified tumor suppressor gene. DLC1 is widely expressed in normal human tissues, but we have shown it is frequently underexpressed in HCC. Rho small GTPases are important regulators in actin cytoskeleton reorganization, cell proliferation, metastasis and tumorigenesis. RhoGAP proteins serve their tumor suppressor function by down-regulating Rho GTPase activity. We have previously characterized DLC1 to be a growth suppressor in HCC cell lines and documented its in vitro RhoGAP activity. Our recent findings have revealed that inhibition of Rho-mediated actin stress fiber formation by DLC1 is associated with its growth suppressive effect. In the present study we have identified tensin2 as the novel binding partner of DLC1 in a yeast two-hybrid library screening. Tensin2 belongs to a new family of focal adhesion proteins that play key roles in cytoskeleton organization and signal transduction. Specific in vitro and in vivo interaction between DLC1 and tensin2 was confirmed by GST pull-down assay and co-immunoprecipitation, respectively. We mapped the minimal interacting domains between two proteins to the phosphotyrosine binding domain of tensin2 and residues 375-509 of DLC1. Dysregulation of tensin proteins has previously been implicated in human cancers. Tensin2 is highly expressed in human liver. Introduction of tensin2 into HCC cell lines with low expression of tensin2 caused significant growth inhibition in colony formation assay and induction of apoptosis. Interaction between DLC1 and tensin2 is of particular interest because both interacting partners exert growth suppressive effect on HCC cell lines. Using reporter assay to investigate the effect of DLC1 and tensin2 on the serum response element (SRE), which is one of the Ras effectors, we found that expression of either DLC1 or tensin2 alone could not inhibit or only slightly inhibited the activation of SRE. The effect of inhibition was enhanced when DLC1 and tensin2 were co-expressed. Our results showed that DLC1 and tensin2 cooperatively inhibited Ras signaling based on their specific interaction. Our findings presented here will derive new insights into the biological functions of tensin2. More importantly, our work suggests a new model for the action of DLC1 in hepatocytes, whereby DLC1-tensin2 complex interacts to effect cytoskeletal reorganization and signaling pathway. We believe that a better understanding of the functional roles of DLC1 and tensin2 will have profound implications for diagnosis and therapeutic intervention of HCC. (This study was funded in part by Association for International Cancer Research and Kadoorie Charitable Foundation - Michael Kadoorie Cancer Genetic Research Program)-
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research-
dc.relation.ispartofCancer Researchen_HK
dc.titleInteraction of deleted in liver cancer 1 (DLC1) with tensin2 and its implications in tumor suppressionen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailKo, FCF: bokcf@hkucc.hku.hken_HK
dc.identifier.emailYam, JWP: judyyam@pathology.hku.hken_HK
dc.identifier.emailChan, PCY: ahyiu@pathology.hku.hken_HK
dc.identifier.emailJin, D: dyjin@hkucc.hku.hken_HK
dc.identifier.emailNg, IOL: iolng@hkucc.hku.hken_HK
dc.identifier.authorityYam, JWP=rp00468en_HK
dc.identifier.authorityJin, D=rp00452en_HK
dc.identifier.authorityNg, IOL=rp00335en_HK
dc.identifier.hkuros120064en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats